Literature DB >> 17090649

Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels.

Carina J M van Schooten1, Cécile V Denis, Ton Lisman, Jeroen C J Eikenboom, Frank W Leebeek, Jenny Goudemand, Edith Fressinaud, H Marijke van den Berg, Philip G de Groot, Peter J Lenting.   

Abstract

The glycosylation profile of von Willebrand factor (VWF) is known to strongly influence its plasma levels. VWF contains several carbohydrate structures, including O-linked glycans that primarily consist of sialylated T antigen (NeuAc(alpha2-3)Gal-(beta1-3)-[NeuAc(alpha2-6)]GalNAc). It is not yet known whether O-linked carbohydrates affect VWF levels. We developed an immunosorbent assay based on neuraminidase incubation allowing subsequent binding of peanut agglutinin (PNA) to desialylated O-linked T antigen on VWF. An inverse relation was found between PNA binding and VWF antigen levels in healthy individuals (n = 111; Pearson rank = -0.43; P < .001). A similar inverse association was observed in randomly selected plasma samples from our diagnostic laboratory: 252% +/- 125% for VWF levels less than 0.5 U/mL (n = 15); 131% +/- 36% for VWF levels between 0.5 and 1.5 U/mL (n = 32); and 92% +/- 40% for VWF levels more than 1.5 U/mL (n = 19). Reduced or increased PNA binding was also observed in patients with increased (liver cirrhosis) or reduced (von Willebrand disease [VWD] type 1) VWF antigen levels, respectively. VWD type 1 patients further displayed increased ratios of propeptide over mature VWF antigen levels (0.38 +/- 0.18 versus 0.17 +/- 0.03 for patients and controls, respectively; P < .001), which is indicative of reduced VWF survival in these patients. Of interest, a linear relation between PNA binding and propeptide/VWF ratio was observed (Spearman rank = 0.47), suggesting a potential association between O-linked glycosylation and VWF survival. Finally, we detected a marked decrease in PNA binding in post-DDAVP (1-deamino-8-D-arginine vasopressin) samples from various patients, indicating that the O-linked glycosylation profile of VWF stored in endothelial storage organelles may differ from circulating VWF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17090649     DOI: 10.1182/blood-2006-06-032706

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Naturally occurring structural isomers in serum IgA1 o-glycosylation.

Authors:  Kazuo Takahashi; Archer D Smith; Knud Poulsen; Mogens Kilian; Bruce A Julian; Jiri Mestecky; Jan Novak; Matthew B Renfrow
Journal:  J Proteome Res       Date:  2011-12-29       Impact factor: 4.466

2.  Prioritizing genetic variants for causality on the basis of preferential linkage disequilibrium.

Authors:  Qianqian Zhu; Dongliang Ge; Erin L Heinzen; Samuel P Dickson; Thomas J Urban; Mingfu Zhu; Jessica M Maia; Min He; Qian Zhao; Kevin V Shianna; David B Goldstein
Journal:  Am J Hum Genet       Date:  2012-08-30       Impact factor: 11.025

3.  Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation.

Authors:  Judicael Fazavana; Teresa M Brophy; Alain Chion; Niamh Cooke; Virginie Terraube; Justin Cohen; Chuenlei Parng; Debra Pittman; Orla Cunningham; Matthew Lambert; James S O'Donnell; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

4.  The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels.

Authors:  Natalia Rydz; Laura L Swystun; Colleen Notley; Andrew D Paterson; J Jacob Riches; Kate Sponagle; Boonchai Boonyawat; Robert R Montgomery; Paula D James; David Lillicrap
Journal:  Blood       Date:  2013-03-25       Impact factor: 22.113

5.  Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.

Authors:  Nadine Vollack-Hesse; Olga Oleshko; Sonja Werwitzke; Barbara Solecka-Witulska; Christoph Kannicht; Andreas Tiede
Journal:  Blood       Date:  2021-02-25       Impact factor: 22.113

6.  Increased active von Willebrand factor during disease development in the aging diabetic patient population.

Authors:  Shuang Feng Chen; Zuo Li Xia; Ji Ju Han; Yi Ting Wang; Ji Yue Wang; Shao Dong Pan; Ya Ping Wu; Bin Zhang; Guang Yao Li; Jing Wei Du; Hen Qiang Gao; Philip G de Groot; Bas de Laat; Martine J Hollestelle
Journal:  Age (Dordr)       Date:  2011-11-27

7.  In vivo analysis of the role of O-glycosylations of von Willebrand factor.

Authors:  Idinath Badirou; Mohamad Kurdi; Paulette Legendre; Julie Rayes; Marijke Bryckaert; Caterina Casari; Peter J Lenting; Olivier D Christophe; Cecile V Denis
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

8.  Desialylation of O-glycans activates von Willebrand factor by destabilizing its autoinhibitory module.

Authors:  Kayleigh M Voos; Wenpeng Cao; Nicholas A Arce; Emily R Legan; Yingchun Wang; Asif Shajahan; Parastoo Azadi; Pete Lollar; Xiaohui Frank Zhang; Renhao Li
Journal:  J Thromb Haemost       Date:  2021-09-26       Impact factor: 16.036

9.  The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitus.

Authors:  Laura Oggianu; Stefano Lancellotti; Dario Pitocco; Francesco Zaccardi; Paola Rizzo; Francesca Martini; Giovanni Ghirlanda; Raimondo De Cristofaro
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

10.  Quantitative Influence of ABO Blood Groups on Factor VIII and Its Ratio to von Willebrand Factor, Novel Observations from an ARIC Study of 11,673 Subjects.

Authors:  Jaewoo Song; Fengju Chen; Marco Campos; Doug Bolgiano; Katie Houck; Lloyd E Chambless; Kenneth K Wu; Aaron R Folsom; David Couper; Eric Boerwinkle; Jing-fei Dong
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.